Activation of nitrofurazone by azoreductases: Multiple activities in one enzyme

Scientific Reports

Volumn 1, Issue , 2011, Pages

  Ryan, Ali ^a,b   Kaplan, Elise ^a   Laurieri, Nicola ^a   Lowe, Edward ^a   Sim, Edith ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZO REDUCTASE; NITROFURAL; OXIDOREDUCTASE;

ARTICLE; BIOTRANSFORMATION; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM;

BIOTRANSFORMATION; MODELS, MOLECULAR; NADH, NADPH OXIDOREDUCTASES; NITROFURAZONE;

EID: 84860144200     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep00063     Document Type: Article

References (31)

1. Nakanishi, M., Yatome, C., Ishida, N. & Kitade, Y. Putative ACP phosphodiesterase gene (acpD) encodes an azoreductase. J Biol Chem 276, 46394-46399 (2001).
2. Wang, C. J. et al. Molecular cloning, characterisation and ligand-bound structure of an azoreductase from Pseudomonas aeruginosa. J Mol Biol 373, 1213-1228 (2007).
3. Cui, K., Lu, A. Y. & Yang, C. S. Subunit functional studies of NAD(P)H:quinone oxidoreductase with a heterodimer approach. Proc Natl Acad Sci USA 92, 1043-1047 (1995).
4. Peppercorn, M. A. & Goldman, P. The role of intestinal bacteria in themetabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 181, 555-562 (1972).
5. Ryan, A., Wang, C. J., Laurieri, N., Westwood, I. & Sim, E. Reaction mechanism of azoreductases suggests convergent evolution with quinone oxidoreductases. Protein Cell 1, 780-790 (2010).
6. Prosser, G. A. et al. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. Biochemical Pharmacology 79, 678-687 (2010).
7. Boelsterli, U. A., Ho, H. K., Zhou, S. & Leow, K. Y. Bioactivation and hepatotoxicity of nitroaromatic drugs. Curr Drug Metab 7, 715-727 (2006). (Pubitemid 44509678)
8. Tangallapally, R. P., Yendapally, R., Daniels, A. J. & Lee, R. E. Nitrofurans as Novel Anti-tuberculosis Agents: Identification, Development and Evaluation. Current Topics in Medicinal Chemistry 7, 509-526 (2007). (Pubitemid 46488291)
9. Whiteway, J. et al. Oxygen-insensitive nitroreductases: analysis of the roles of nfsA and nfsB in development of resistance to 5-nitrofuran derivatives in Escherichia coli. J Bacteriol 180, 5529-5539 (1998). (Pubitemid 28489842)
10. Knox, R. J. et al. Bioactivation of 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substratemediated antitumor prodrug therapy. Cancer Res 60, 4179-4186 (2000). (Pubitemid 30636602)
11. Race, P. R. et al. Structural and mechanistic studies of Escherichia coli nitroreductase with the antibiotic nitrofurazone. Reversed binding orientations in different redox states of the enzyme. J Biol Chem 280, 13256-13264 (2005). (Pubitemid 40517209)
12. Hiraku, Y. et al. Mechanism of carcinogenesis induced by a veterinary antimicrobial drug, nitrofurazone, via oxidative DNA damage and cell proliferation. Cancer Lett 215, 141-150 (2004). (Pubitemid 39370031)
13. Ryan, A. et al. A novel mechanism for azoreduction. JMol Biol 400, 24-37 (2010).
14. Wang, C. J. et al. Role of Tyrosine 131 in the active site of paAzoR1, an azoreductase with specificity for the inflammatory bowel disease pro-drug balsalazide. Acta Crystallogr F Struct Biol Cryst Commun 66, 2-7 (2010).
15. Liger, D. et al. Crystal structure and functional characterization of yeast YLR011wp, an enzyme with NAD(P)H-FMN and ferric iron reductase activities. J. Biol. Chem. 279, 34890-34897 (2004). (Pubitemid 39318124)
16. Liu, G. et al. Site-directed mutagenesis of substrate binding sites of azoreductase from Rhodobacter sphaeroides. Biotechnol Lett 30, 869-875 (2008).
17. Haynes, C. A., Koder, R. L., Miller, A. F. & Rodgers, D. W. Structures of nitroreductase in three states: effects of inhibitor binding and reduction. J Biol Chem 277, 11513-11520 (2002). (Pubitemid 34952921)
18. Johansson, E., Parkinson, G. N., Denny, W. A. & Neidle, S. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form. J Med Chem 46, 4009-4020 (2003). (Pubitemid 37122447)
19. Kari, F. NTP Toxicology and Carcinogenesis Studies of Nitrofurazone (CAS No. 59-87-0) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 337, 1-183 (1988).
20. Fu, Y., Buryanovskyy, L. & Zhang, Z. Crystal structure of quinone reductase 2 in complex with cancer prodrug CB1954. Biochem Biophys Res Commun 336, 332-338 (2005). (Pubitemid 41253438)
21. Li, R., Bianchet, M. A., Talalay, P. & Amzel, L. M. The three-dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction. Proc Natl Acad Sci USA 92, 8846-8850 (1995).
22. Kabsch, W. XDS. Acta Crystallographica Section D 66, 125-132 (2010).
23. Bailey, S. The CCP4 suit-programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 58, 760-763 (1994).
24. Winter, G. xia2: an expert system for macromolecular crystallography data reduction. J Appl Crystallogr 43, 186-190 (2010).
25. McCoy, A. J. et al. Phaser crystallographic software. J Appl Crystallogr 40, 658-674 (2007). (Pubitemid 47080256)
26. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66, 486-501 (2010).
27. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53, 240-255 (1997). (Pubitemid 27235885)
28. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66, 213-221 (2010).
29. Painter, J. & Merritt, E. A. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr D Biol Crystallogr 62, 439-450 (2006).
30. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66, 12-21 (2010).
31. DeLano, W. L., Edn. Version 1. 1 (DeLano Scientific, Palo Alto, ,. CA, , USA; 2008).